Chinese Academy of Sciences

Topharman Shanghai Co., Ltd.

Suzhou Vigonvita Life Sciences Co., Ltd.

Topharman Shandong Co., Ltd.

China Railway Engineering Equipment Group Co., Ltd.

Weiming Chen

Rongxia Zhang

Jingshan Shen

Hualiang Jiang

Zhen Wang

Yang He

Guanghui Tian

Jianfeng Li

Xiangrui Jiang

Yu Ying Wang

Guan Zhong Wang

Yongjian Liu

Chunhui Wu

Fuqiang Zhu

Feipu Yang

Xudong Gong

Zheng Liu

Wei Xiao

Wei Shi

Lin Feng

Jianbin Li

Ying Zhu

Jin Suo

Lianhui Jia

Xianguo Zhao

Xiaoguang Kong

Jingjing Yin

Minghao Bi

Wei Wang

Xingjian Zhuo

Dujuan Wang

Xidong Zhang

Juhui Yang

Lixun Zhang

Qingzeng Yu

Dan Lv

Qian Zhou

Tianren Yang

Yu Wang

The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.

Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition

The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof. 

Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof

The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation. 

Maleate salt of benzothiophene compound, crystalline form thereof, and use thereof

The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease. 

Heterocyclic compounds, process for preparation of the same and use thereof

This invention disclose (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone in a single configuration and preparation method and use thereof. The (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone, or a pharmaceutically acceptable salt, an ester, a prodrug or a solvate thereof according to the invention are important intermediates of a variety of anti-viral and anti-tumor active ingredients. A compound obtained from (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone via an acylation reaction can be directly used for preparing various anti-viral and anti-tumor drugs. The Chiral synthesis method and the spontaneous resolution method of the compound of (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone according to the invention have the following advantages: the reaction routes are short and simple with high yield and low cost, which are suitable for industrial application. 

(2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof

Provided is a process for preparing racemic nicotine from 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof using one-pot process. The process comprises the following steps: 1) in a reaction vessel, reacting 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof in the presence of a suitable solvent and a strong acid by heat; after the reaction is complete, cooling the same and adjusting the pH to 7-8 with alkali; and 2) directly adding a reductant into the above vessel, and after the reaction, purifying the product so as to obtain high purity racemic nicotine or a salt thereof.

Process for preparing racemic nicotine

Growing community of inventors

Shanghai, China

Weiming Chen